The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)
27
0
2
12
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
0.0%
0 terminated/withdrawn out of 27 trials
100.0%
+13.5% vs industry average
30%
8 trials in Phase 3/4
0%
0 of 12 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (27)
Trial LEP-F1 + GLA-SE in Healthy Adult in Areas Endemic for Leprosy
Role: lead
Effectiveness of Vaccination Against COVID-19 in Brazil: Case-Control Study
Role: lead
Efficacy and Safety Evaluation of the Intralesional Recombinant Human Epidermal Growth Factor (rhEGF) in Subjects With Diabetic Foot Ulcer.
Role: lead
Investigation of Serious Adverse Events Following Vaccination Against Yellow Fever: Emphasis on Genetic Basis and Biological Markers
Role: lead
Phase 1b/2a Trial to Evaluate LEP-F1 + GLA-SE in Healthy Adults and Leprosy Patients
Role: lead
Immunogenicity Study of the Covid-19 (Recombinante) Vaccine With a 4 or 8 Week Interval Between the First Doses.
Role: lead
Gene Sequencing as a Strategy for Identifying Genetic Factors Associated With Serious Adverse Events After Covid-19 Vaccines in Use in Brazil
Role: lead
Immunity Period After One Dose of Yellow Fever Vaccine in Adults and Children (Paraiba Study)
Role: lead
Secondary Attack Rate Measles Vaccine In Second Situation Contacts Cases Confirmed
Role: lead
Immunity Duration Study Eight Years After Vaccination of Children 12 to 23 Months With the Triple Viral Vaccine (Measles, Mumps and Rubella)
Role: lead
Study of Immunogenicity Equivalence of a Homologous Third Dose of Covid-19 (Recombinante) Vaccine
Role: lead
Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella
Role: lead
Duration of Immunity 10 Years After a Dose-response Study With Yellow Fever Vaccine - Complementary Study
Role: lead
Validation of Rapid Tests for the Serological Diagnosis of HIV in 9 to 24 Months Old Children
Role: lead
Usability Study of a Self-test Prototype for Human Immunodeficiency Virus (HIV) Screening
Role: lead
Conjugate Vaccine Against Meningococcus C a Brazilian Project
Role: lead
Clinical Study of Immunity Duration of Yellow Fever Vaccine in Military
Role: lead
Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months.
Role: lead
Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations
Role: lead
Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella
Role: lead